IDEXX Laboratories, Inc. (NASDAQ:IDXX) insider Giovani Twigge sold 1,626 shares of the firm’s stock in a transaction on Tuesday, May 29th. The shares were sold at an average price of $204.37, for a total value of $332,305.62. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Shares of IDEXX Laboratories opened at $222.90 on Friday, Marketbeat reports. IDEXX Laboratories, Inc. has a 1 year low of $146.09 and a 1 year high of $229.01. The firm has a market cap of $19.28 billion, a PE ratio of 67.96, a price-to-earnings-growth ratio of 2.63 and a beta of 0.64. The company has a quick ratio of 0.72, a current ratio of 0.96 and a debt-to-equity ratio of -12.43.
IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Friday, May 4th. The company reported $1.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.92 by $0.09. IDEXX Laboratories had a negative return on equity of 530.24% and a net margin of 13.87%. The firm had revenue of $537.60 million during the quarter, compared to analyst estimates of $525.14 million. During the same period last year, the firm posted $0.77 EPS. The business’s revenue was up 16.4% compared to the same quarter last year. equities analysts expect that IDEXX Laboratories, Inc. will post 4.17 earnings per share for the current fiscal year.
Institutional investors have recently made changes to their positions in the company. Signaturefd LLC purchased a new stake in IDEXX Laboratories in the 1st quarter worth about $105,000. Three Peaks Capital Management LLC purchased a new stake in IDEXX Laboratories in the 1st quarter worth about $108,000. Optimum Investment Advisors purchased a new stake in IDEXX Laboratories in the 1st quarter worth about $139,000. W.G. Shaheen & Associates DBA Whitney & Co purchased a new stake in IDEXX Laboratories in the 1st quarter worth about $191,000. Finally, Financial Gravity Wealth Inc. purchased a new stake in IDEXX Laboratories in the 1st quarter worth about $191,000. 86.28% of the stock is owned by hedge funds and other institutional investors.
Several equities analysts have weighed in on the company. Zacks Investment Research cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Tuesday, April 3rd. Canaccord Genuity restated a “positive” rating and set a $215.00 price objective on shares of IDEXX Laboratories in a research note on Monday, May 7th. Credit Suisse Group raised their price objective on IDEXX Laboratories from $228.00 to $231.00 and gave the company an “outperform” rating in a research note on Thursday. BidaskClub cut IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, May 9th. Finally, Stifel Nicolaus raised their price objective on IDEXX Laboratories from $215.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, May 7th. One equities research analyst has rated the stock with a sell rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $222.43.
About IDEXX Laboratories
IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.